Distributor inventory
Paliperidone palmitate 50 mg/0.5 mL (long-acting injectable suspension)
Treatment of schizophrenia in adults; may be used for maintenance therapy with a long-acting antipsychotic as prescribed.
Paliperidone is an atypical antipsychotic that mainly blocks dopamine (D2) and serotonin (5‑HT2A) receptors, helping reduce psychotic symptoms. The palmitate ester is a long‑acting depot form that slowly releases paliperidone after intramuscular injection for sustained effect.
Prescription-only long-acting injection. Administer as an intramuscular injection by a healthcare professional (deltoid or gluteal muscle as advised). Follow the exact dosing schedule set by the psychiatrist; do not self-inject, shake, or mix unless instructed in the product leaflet.
Common side effects of PALIRIS LA 50MG PFS may include:
Use only under specialist supervision. May cause drowsiness and dizziness—avoid driving until you know the effect. Risk of extrapyramidal symptoms/tardive dyskinesia, neuroleptic malignant syndrome, increased prolactin, weight gain and metabolic changes (blood sugar/lipids), orthostatic hypotension, seizures, QT prolongation/heart rhythm problems. Increased risk of stroke and death in elderly patients with dementia-related psychosis (not approved). Use caution in diabetes, obesity, Parkinsonism, epilepsy, cardiovascular disease, and in patients with history of blood clots. Monitor weight, glucose, lipids, and movement disorders as advised.
